Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

Non-Malignant Blood Disorders

Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study

Lancet Haematol.

Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Bolaños-Meade J, Panepinto JA, Rondelli D, Shenoy S, Williamson J, Woolford TL, Gluckman E, Wagner JE, Tisdale JF

doi: 10.1016/S2352-3026(19)30154-1.

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Lung Cancer.

Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S

doi: 10.1016/j.lungcan.2019.10.002.

Lung, Respiratory and Thoracic Cancer

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Lung Cancer.

Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D

doi: 10.1016/j.lungcan.

Non-Malignant Blood Disorders

Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study

Am J Hematol.

Brousse V, El Hoss S, Bouazza N, Arnaud C, Bernaudin F, Pellegrino B, Guitton C, Odievre-Montanié MH, Mames D, Brouzes C, Picard V, Nguyen-Khoa T, Pereira C, Lapoumeroulie C, Pissard S, Gardner K, Menzel S, Le Van Kim C, Colin Aronovicz Y, Buffet P, Mohandas N, Elie C, Maier-Redelsperger M, El Nemer W, De Montalembert M

doi: 10.1002/ajh.25260.

SPECIAL REPORT

Skin Cancer

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2

RECOMMENDED

Genitourinary Cancer

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

Lancet Oncol.

Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ

doi: 10.1016/S1470

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Oncol.

Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodríguez-Abreu D

doi: 10.1016/S1470-2045(19)30801-0.

Non-Malignant Blood Disorders

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Haematol

Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, Inati A, Wali Y, Kristensen J, Kowalski J, Donnelly E, Ohd J, TVOC01 Investigators Group.

doi: 10.1016/S2352-3026(21)00053-3

Non-Malignant Blood Disorders

COVID-19 Infection in Patients with Sickle Cell Disease

Br J Haematol.

Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J

doi: 10.1111/bjh.16734.

Related content

Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study

Bavencio® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma1,2

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

COVID-19 Infection in Patients with Sickle Cell Disease

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2